MX2020005167A - Metodo para el tratamiento de enfermedades gastrointestinales con tradipitant. - Google Patents

Metodo para el tratamiento de enfermedades gastrointestinales con tradipitant.

Info

Publication number
MX2020005167A
MX2020005167A MX2020005167A MX2020005167A MX2020005167A MX 2020005167 A MX2020005167 A MX 2020005167A MX 2020005167 A MX2020005167 A MX 2020005167A MX 2020005167 A MX2020005167 A MX 2020005167A MX 2020005167 A MX2020005167 A MX 2020005167A
Authority
MX
Mexico
Prior art keywords
treatment
tradipitant
gastrointestinal diseases
gastric motility
disclosed
Prior art date
Application number
MX2020005167A
Other languages
English (en)
Spanish (es)
Inventor
Mihael H Polymeropoulos
Gunther Birznieks
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2020005167A publication Critical patent/MX2020005167A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2020005167A 2017-11-17 2018-11-16 Metodo para el tratamiento de enfermedades gastrointestinales con tradipitant. MX2020005167A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762587681P 2017-11-17 2017-11-17
PCT/US2018/061593 WO2019099883A1 (en) 2017-11-17 2018-11-16 Method of treatment of gastrointestinal diseases with tradipitant

Publications (1)

Publication Number Publication Date
MX2020005167A true MX2020005167A (es) 2020-08-20

Family

ID=64734107

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005167A MX2020005167A (es) 2017-11-17 2018-11-16 Metodo para el tratamiento de enfermedades gastrointestinales con tradipitant.

Country Status (19)

Country Link
US (4) US20200030307A1 (https=)
EP (1) EP3710000B1 (https=)
JP (1) JP7306614B2 (https=)
KR (2) KR20250140655A (https=)
CN (2) CN111343981A (https=)
AU (1) AU2018367623B2 (https=)
BR (1) BR112020009520A2 (https=)
CA (1) CA3081582A1 (https=)
CL (1) CL2020001290A1 (https=)
DK (1) DK3710000T3 (https=)
ES (1) ES3032138T3 (https=)
FI (1) FI3710000T3 (https=)
HR (1) HRP20250615T1 (https=)
HU (1) HUE071527T2 (https=)
IL (1) IL274541B2 (https=)
MX (1) MX2020005167A (https=)
PT (1) PT3710000T (https=)
SI (1) SI3710000T1 (https=)
WO (1) WO2019099883A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2978736C (en) * 2015-03-04 2023-11-07 Vanda Pharmaceuticals Inc. Dosing regimen of tradipitant
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
KR102863233B1 (ko) * 2018-09-28 2025-09-22 반다 파마슈티칼즈, 인코퍼레이티드. 멀미에서의 트라디피탄트의 용도
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
CN120641099A (zh) 2022-12-21 2025-09-12 万达制药公司 使用曲地匹坦的治疗方法
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100755577B1 (ko) 2002-04-26 2007-09-12 일라이 릴리 앤드 캄파니 타키키닌 수용체 길항제로서의 트리아졸 유도체
NZ580480A (en) 2003-10-24 2010-02-26 Lilly Co Eli Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
CN101568523A (zh) 2006-12-20 2009-10-28 伊莱利利公司 用于制备{2-[1-(3,5-二-三氟甲基-苄基)-5-吡啶-4-基-1h-[1,2,3]三唑-4-基]-吡啶-3-基}·(2-氯苯基)甲酮的新中间体和方法
PT2722045T (pt) * 2009-11-18 2016-10-18 Helsinn Healthcare Sa Composições para o tratamento de náuseas e vómitos mediadas centralmente
CA2978736C (en) * 2015-03-04 2023-11-07 Vanda Pharmaceuticals Inc. Dosing regimen of tradipitant
WO2017112792A1 (en) 2015-12-22 2017-06-29 Takeda Pharmaceutical Company Limited Tripartite modulators of endosomal g protein-coupled receptors

Also Published As

Publication number Publication date
SI3710000T1 (sl) 2025-07-31
CN111343981A (zh) 2020-06-26
CL2020001290A1 (es) 2020-11-13
KR20200088346A (ko) 2020-07-22
IL274541A (en) 2020-06-30
IL274541B1 (en) 2024-06-01
WO2019099883A1 (en) 2019-05-23
NZ764107A (en) 2024-07-05
AU2018367623A1 (en) 2020-05-21
KR20250140655A (ko) 2025-09-25
EP3710000A1 (en) 2020-09-23
IL274541B2 (en) 2024-10-01
ES3032138T3 (en) 2025-07-15
JP2021503480A (ja) 2021-02-12
PT3710000T (pt) 2025-05-29
KR102864285B1 (ko) 2025-09-24
CA3081582A1 (en) 2019-05-23
US20230390269A1 (en) 2023-12-07
US20210093621A1 (en) 2021-04-01
US20210330656A1 (en) 2021-10-28
JP7306614B2 (ja) 2023-07-11
DK3710000T3 (da) 2025-06-16
EP3710000B1 (en) 2025-04-23
BR112020009520A2 (pt) 2020-11-03
CN119074729A (zh) 2024-12-06
FI3710000T3 (fi) 2025-07-03
HRP20250615T1 (hr) 2025-07-18
HUE071527T2 (hu) 2025-09-28
AU2018367623B2 (en) 2024-03-28
RU2020119259A (ru) 2021-12-17
US20200030307A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MX2020005167A (es) Metodo para el tratamiento de enfermedades gastrointestinales con tradipitant.
HUE064141T2 (hu) Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
HUE057926T2 (hu) Eljárás tiokarbonátok elõállítására
DK3493874T3 (da) Neuromodulationselektrodeanordning
ZA202103713B (en) Mobility procedure
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
IL269174A (en) Methods for treating complement-mediated diseases and disorders
EP3237057A4 (en) Devices, systems and methods for treating urological and gastrointestinal disorders by electrical stimulation of the foot
EP3720865C0 (en) NEW SPIROBICYCLIC ANALOGS
EP3670654A4 (en) XYLANASE MUTANT
MX2020011668A (es) Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
MX2020008507A (es) Metodo para producir 1,1,3,3-tetracloropropeno.
EP3458060C0 (en) COMBINATION THERAPY FOR MALE SEXUAL DYSFUNCTION
GB2571529B (en) Formation of piezoelectric devices
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
IL271395A (en) Treatment of sexual dysfunction and improvement in sexual quality of life
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
DK3307323T3 (da) Carbazolderivater til behandling af fibrotiske sygdomme og relaterede symptomer, og tilstande deraf
IL282905A (en) Cycloalkane-1, 3-diamine derivative
EP3636271C0 (en) THERAPEUTIC AGENT AGAINST DILATED CARDIOMYOPATHY
EP3447299C0 (de) Einstellring
IL270362B (en) Glaucoma treatment
EP3863709C0 (en) Electro-stimulation apparatus
IL274190A (en) Methods for treating ischemic disease
IL272023A (en) Methods of treating symptoms of gastroparesis using velusetrag